Italian study tracks new combo therapy for advanced lung cancer in everyday practice
NCT ID NCT07190677
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Italian study is collecting real-world data from 300 patients with advanced non-small cell lung cancer who are receiving a combination of nivolumab, ipilimumab, and chemotherapy as their first treatment. The goal is to see how long patients live and how long the cancer stays under control in everyday clinical settings, not just in clinical trials. Researchers are also tracking side effects and how well the treatment works in different patient groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab plus ipilimumab plus chemotherapy
What this could lead to
If successful, this study could confirm that this drug combination works well in real-world patients, not just in controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be less reliable. It also only includes patients in Italy, which may limit how well findings apply elsewhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Policlinico San Matteo
RECRUITINGPavia, Lombardy, 27100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••